BMJ Quality & Safety

What goes wrong in out-of-hours primary care in Denmark? A compensation claim analysis using the healthcare complaints analysis tool

Background Out-of-hours primary care (OOH-PC) services are complex clinical environments where suboptimal care may occur.

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive ...

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with unresectable or ...